French, multinational pharmaceutical company Sanofi SA said on 22 February 2021 that it will provide COVID-19 vaccine manufacturing support to US pharmaceutical company Johnson & Johnson Inc (J&J), Reuters news agency reported on Monday.
Reportedly, once authorised, Sanofi will provide Johnson & Johnson access to the infrastructure and expertise of its vaccine manufacturing plant in Marcy l'Etoile, France, to formulate and fill vials of Johnson & Johnson's Janssen COVID-19 vaccine candidate in 2021.
These vials will be filled at a rate of approximately 12 million doses per month, Sanofi added.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne